Form 4: Kymera Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Nello Mainolfi, Chief Executive Officer and a Director of Kymera Therapeutics, Inc., sold 30,000 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 30,000 Common Stock at $2.08 ($62,400) on October 1, 2026; holds 696,568 after (Direct).
- Open-market sale: disposed of 3,525 Common Stock at $111.44 ($392,826) on October 1, 2026; holds 693,043 after (Direct).
- Open-market sale: disposed of 5,506 Common Stock at $112.42 ($618,985) on October 1, 2026; holds 687,537 after (Direct).
- Open-market sale: disposed of 4,876 Common Stock at $113.24 ($552,158) on October 1, 2026; holds 682,661 after (Direct).
- Open-market sale: disposed of 7,601 Common Stock at $114.43 ($869,782) on October 1, 2026; holds 675,060 after (Direct).
- Open-market sale: disposed of 8,230 Common Stock at $115.40 ($949,742) on October 1, 2026; holds 666,830 after (Direct).
- Open-market sale: disposed of 262 Common Stock at $116.12 ($30,423) on October 1, 2026; holds 666,568 after (Direct).
- Option exercise/conversion: disposed of 30,000 Stock Option (Right to Buy) on October 1, 2026; holds 60,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,413,917 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Nello Mainolfi — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 30,000 | $2 | $62.4K | 696,568 |
| 2026-10-01 | Open-market sale | Common Stock | 3,525 | $111 | $392.8K | 693,043 |
| 2026-10-01 | Open-market sale | Common Stock | 5,506 | $112 | $619.0K | 687,537 |
| 2026-10-01 | Open-market sale | Common Stock | 4,876 | $113 | $552.2K | 682,661 |
| 2026-10-01 | Open-market sale | Common Stock | 7,601 | $114 | $869.8K | 675,060 |
| 2026-10-01 | Open-market sale | Common Stock | 8,230 | $115 | $949.7K | 666,830 |
| 2026-10-01 | Open-market sale | Common Stock | 262 | $116 | $30.4K | 666,568 |
| 2026-10-01 | Option exercise/conversion | Stock Option (Right to Buy) | 30,000 | — | — | 60,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (30,000 shares) |
| 2026-10-01 | Open-market sale (3,525 shares) |
| 2026-10-01 | Open-market sale (5,506 shares) |
| 2026-10-01 | Open-market sale (4,876 shares) |
| 2026-10-01 | Open-market sale (7,601 shares) |
| 2026-10-01 | Open-market sale (8,230 shares) |
| 2026-10-01 | Open-market sale (262 shares) |
| 2026-10-01 | Option exercise/conversion (30,000 shares) |
Keywords
insider transaction, Form 4, KYMR, Kymera Therapeutics, Inc., bearish, Nello Mainolfi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.